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Objective: To study the seroprevalence of hepatitis B virus (HBV) and hepatitis delta
virus (HDV) infections in patients visiting outpatient department of a major tertiary care
hospital in Khyber Pakhtunkhwa region of Pakistan.
Methods: Blood samples were collected from non-hospitalized patients. Serological
analysis was done by ELISA and viral DNA was ampliﬁed by PCR. The ampliﬁed DNA
was analyzed by agarose gel electrophoresis.
Results: Altogether, 946 blood samples were screened, overall percentage of HBsAg-
positive patients remained 22.41% (prevalence: 224.10/1000; CI: 0.1975 ± 0.2507) with
the highest incidence rates among relatively younger age groups (20–29 years). The
prevalence of HBV–HDV co-infection was found to be 46.75/1000; CI: 0.0318 ± 0.0617.
In HBsAg-positive patients, anti-HBc-total was detected in 86.79% while 25.00% were
positive for anti-HBc-immunoglobulinM. Similarly, among these patients, HBVDNAwas
detected in 64.13% and 10.85% were co-infected with HDV. Different symptoms were
associated with the prevailing infection, including malaise (62%), anorexia (66%) and fa-
tigue (73%). The most commonly associated symptom was abdominal discomfort. Among
these patients, certain risk factors, including surgery, visit to dentist and intravenus infusions
were frequently associated with the infection (c2 = 95.23; df = 11; P < 0.0001).
Conclusions: Overall, this study conﬁrmed higher prevalence of active HBV/HDV
infection, among young patients from Khyber Pakhtunkhwa region having no prior
history of viral hepatitis.1. Introduction
Hepatitis delta virus (HDV) is a defective negative-sense
RNA virus that requires hepatitis B virus (HBV) for its assem-
bly [1]. The genome of HDV is circular and consists of 1700
nucleotides in length [2]. Both HBV and HDV have the same
route of transmission [3]. It is estimated that out of 350 millionHBV carriers, 18 million people are co-infected with HDV [4].
Co/super-infections due to HDV leads to severe acute liver
disease and increases the risk of developing fulminant hepatitis
[5]. Different studies conducted around the globe reported
varying prevalence rates of HDV. For example, in Middle-
East prevalence rate was reported to be 3.3% among the gen-
eral population, while particularly in Saudi-Arabia, it was 8.6%
in the hospitalized patients. In Oman, up to 7.7% of the regis-
tered dialysis patients were infected with HDV [6,7]. Similarly,
from China prevalence rates were reported to be 7.2% in
Shandong and 3.5% in Henan provinces [8].
From Pakistan different prevalence rates for HDV infection
have been reported, ranging from 16.5% to 58.6% [9,10]. However,
with the exception of few reports, most of these studies focused on
stratiﬁed groups like hepatitis patients or patients at higher risk of
HDV infection. Hence, little is known about the prevalence ofarticle under the CC BY-NC-ND license (http://
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was carried out in the Khyber Pakhtunkhwa (KPK) Province of
Pakistan and highlights the current prevalence rates of HBV/
HDV infection and associated risk factors among patients having
no prior history of viral hepatitis.
2. Materials and methods
2.1. Study population and sampling site
This cross-sectional studywas carried out fromAugust 2011 to
August 2013. Sampling was conducted at outpatient department
of Hayatabad Medical Complex (HMC) Peshawar, located in
KPK region of Pakistan. Peshawar city is the provincial capital
with a multi-ethnic assemblage and comprises a representative
population originating from all areas of KPK. The study protocol
was designed according to the Helsinki declaration. Ethical
approval was granted by institutional research and ethics board of
HMC. Prior to the collection of samples, a formal consent was
obtained from each patient or his/her guardian/parent. A detailed
questionnaire was designed to collect demographic proﬁle,
including age, gender, socioeconomic status, anthropometric data,
vaccination history, and information related to various risk be-
haviors. HMC is a major tertiary care hospital that receives a large
inﬂux of patients from all corners of KPK region.
2.2. Inclusion criteria and sampling procedure
Patients visiting outpatient department having no prior his-
tory of viral hepatitis were included in this study while previ-
ously vaccinated individuals against HBV were excluded.
Peripheral blood samples (4.0 mL) were collected by using
5.0 mL sterile BD syringe. A brief centrifugation step was
performed for serum separation.
2.3. Serological analysis
Patients with elevated liver function tests were included for
further evaluation based on relevant serological and molecular
parameters. Samples were screened for the detection of HBsAg.
Positive samples were evaluated for anti-HBc-IgM, anti-HBc-
IgG, anti-HDV and anti-HCV. For this purpose, commercially
available ELISA kits (MBS-SRL, Milano, Italy) were used ac-
cording to the instructions provided by the manufacturer.
2.4. DNA extraction and ampliﬁcation
Viral DNA was extracted by using commercially available
kits (Sacace Biotechnologies S.r.l, Italy). For the ampliﬁcation
of DNA, previously reported sets of primers were used, ampli-
ﬁcation conditions were essentially the same as previously re-
ported [11]. DNA fragments were resolved on 1% agarose gels
and size of each ampliﬁed product was estimated by
comparing it with 1 kb DNA ladder (Solis BioDyne).
2.5. Statistical analysis
The data were recorded in MS-excel and the standard
descriptive analysis was done by using MS-excel and Graph-Pad Prism software (ver. 5). The distributions of various attri-
butes of infections were explored across different demographic
variables. Distributions were separately established for the male
and female samples. Co-infections, clinical details, and risk
factors were analyzed accordingly. Chi-test was performed to
check the signiﬁcance of distributions among different
variables.
3. Results
3.1. Sample characteristics and prevalence of HBV
A total of 946 non-hospitalized patients were screened out
of which 53% (n = 501) were males and 47% (n = 445) fe-
males. Overall the prevalence rate of HBsAg was 22.41%
(prevalence: 224.10/1000; CI: 0.1975 ± 0.2507, shown in
Table 1). Relatively higher prevalence of HBV infection was
observed in the male patients (prevalence: 227.54/1000) in
comparison to the female patients, prevalence: 220.22/1000;
OR: 1.04 (Tables 1 and 2). However, differences between the
distributions of gender speciﬁc samples were not signiﬁcant
statistically (P > 0.05). To estimate the prevalence of HBV
infection among different age groups, data were divided into
six age categories. The prevalence of HBV infection was
highest among younger age groups (Table 1). Although, a
declining trend of HBV prevalence was evident between
different age-intervals, differences in overall distribution of
HBV infection across different age-groups were not signiﬁ-
cant statistically (c2 = 4.57, df = 5; P = 0.47). No signiﬁcant
differences were evident when infected individuals were
cross-tabulated in different age categories against gender
(shown in Table 2).
3.2. Prevalence of co-infection with HDV and HCV
The prevalence of co-infection, i.e., HBV with either HCV
or HDV was witnessed in 36 patients (Table 2). Among the
co-infected patients, 19 were males and 17 females. Overall,
10.85% (23/212) of the samples were reactive against HDV
and 7.55% (16/212) against HCV. Out of all HDV infected
patients, 43.48% (10/23) were males while 56.52% (13/23)
were females (c2 = 0.851; df = 1; P = 0.356) (Table 2). Unlike
HDV infected individuals, higher percentage of HCV positive
individuals 62.5% (10/16) were males in comparison to
37.5% (6/16) females (c2 = 0.595; df = 1; P = 0.441; not
signiﬁcant).
3.3. Detection of anti-HBc-total antibodies and viral
DNA
Among the 212 HBsAg-positive patients, anti-HBc-total was
detected in 86.79%. Likewise, anti-HBc-IgM was detected in
25% of the patients out of which four (7.53%) were positive for
anti-HDV and three (5.66%) for anti-HCV (Table 3). Viral DNA
was detected in 64.13% (n = 136) of the HBsAg-positive pa-
tients and 11.51% (n = 16) of these were co-infected with HDV.
Similarly, 5.14% (n = 7) of these patients were co-infected with
HCV. Majority of the patients positive for HBV DNA were
young males. Among co-infected (with either HDV or HCV),
Table 2
Gender differentials in the distribution of infections and age-speciﬁc
samples.
Infection
type/variable
Male Female Total
Hepatitis B HBV 114 98 212
Non-HBV 387 347 734
Total 501 445 946
c2 = 0.073, df = 1, P = 0.788, NS
Hepatitis D HDV 10 13 23
Non-HDV 491 432 923
c2 = 0.851, df = 1, P = 0.356, NS
Hepatitis C HCV 10 6 16
Non-HCV 491 439 930
c2 = 0.595, df = 1, P = 0.441, NS
Co-infection HBV + HCV/HDV 19 17 36
HBV only 95 81 176
Un-infected 387 347 734
c2 = 0.089, df = 2, P = 0.956, NS
HBV in
age-categories
(years)
Up to 9 12 7 19
10–19 28 34 62
20–29 39 26 65
30–39 15 17 32
40–49 9 9 18
50 and above 11 5 16
c2 = 5.696, df = 5, P = 0.337, NS
Total 501 445 946
Table 3
Detection of anti-HBc-IgM, anti-HBc-IgG and viral DNA among the HBsA
Type of infection No. of subjects
Infection type HBV + ve (total) 212
HBV + ve (male) 114
HBV + ve (female) 98
HDV 23
HCV 16
HBV + HCV/HDV 36
Only HBV 176
Age categories (years) Up to 9 19
10–19 62
20–29 65
30–39 32
40–49 18
50 and above 16
+ ve: Positive.
Table 1
Prevalence of HBV in total, gender-wise and age-wise samples of scrutinized population.
Prevalence of hepatitis Infected Uninfected Total Prevalence/1000 Proportion 95% CI Odd ratios*
HBV 212 734 946 224.10 0.2241 0.1975 ± 0.2507 16.7882
HDV 23 923 946 24.31 0.0243 0.0145 ± 0.0341 1.4484
HCV 16 930 946 16.91 0.0169 0.0087 ± 0.0251 Reference
HBV + HCV/HDV 36 734 770 46.75 0.0468 0.0318 ± 0.0617 2.8508
Gender-wise HBV (male) 114 387 501 227.54 0.2275 0.1908 ± 0.2643 1.0430
HBV (female) 98 347 445 220.22 0.2202 0.1817 ± 0.2587 Reference
Age-categories (years) Up to 9 19 57 76 250.00 0.2500 0.1526 ± 0.3474 1.5185
10–19 62 189 251 247.01 0.2470 0.1937 ± 0.3004 1.4944
20–29 65 202 267 243.45 0.2434 0.1920 ± 0.2949 1.4658
30–39 32 143 175 182.86 0.1829 0.1256 ± 0.2401 1.0194
40–49 18 82 100 180.00 0.1800 0.1047 ± 0.2553 Reference
50 and above 16 61 77 207.79 0.2078 0.1172 ± 0.2984 1.1949
*: The least value in each category was taken as reference.
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the patients, respectively (Table 3).
3.4. Symptoms and associated risk factors
Different clinical symptoms were observed among infected
patients, including abdominal discomfort, fatigue, anorexia,
malaise, fever, dark urine, jaundice, and splenomegaly (Table 4).
Most of the symptoms were signiﬁcantly associated with in-
fections (c2 = 103.9; df = 7; P < 0.0001). Abdominal discomfort
was one of the most frequently reported symptoms associated
with HBV infection (79%) that was followed by fatigue (73%),
anorexia (66%) and malaise (62%). Similarly, fever, dark urine
and jaundice were higher among HBV infected patients
(Table 4). Different risk factors were found to be associated with
the infections. Particularly, the association of certain factors like
injection, intravenus infusion, hospitalization, dentist visit, and
surgery, were considerably higher among the infected groups of
patients (Table 5). All other enlisted risk factors showed sig-
niﬁcant association with the infections (c2 = 95.23; df = 11;
P < 0.0001).g-positive patients.
No. of HBc-IgM No. of HBc-IgG No. of DNA detected
53 184 136
37 104 72
16 80 64
4 17 16
3 14 7
7 31 22
46 153 114
4 19 12
20 53 38
13 55 45
10 27 19
3 17 15
3 13 7
Table 5
Risk factors associated with hepatitis infections among the scrutinized patients.
Clinical symptoms* Prevalent hepatitis types and co-infection Un-infected
(n = 734)
Total
(n = 46)
HBV (n = 212) HDV (n = 23) HCV (n = 16) HBV + HCV/HDV (n = 36)
Injection 87.74 73.91 81.25 80.56 37.19 459
Intravenus infusion 83.96 86.96 87.50 88.89 10.76 257
Hospitalization 46.70 47.83 50.00 50.00 20.84 252
Skin piercing 43.87 47.83 50.00 47.22 35.83 356
Visit to barber (male) 69.30 40.00 70.00 57.89 47.70 318
Dentist visit 39.62 47.83 37.50 44.44 6.13 129
Surgery 25.47 13.04 31.25 19.44 12.40 145
Blood transfusion 8.02 13.04 12.50 8.33 6.13 62
Contact with jaundice person 6.60 4.35 12.50 8.33 10.22 89
Tattoos/acupuncture 5.19 13.04 0.00 5.56 6.13 56
Visit to beauty parlor (female) 6.12 7.69 0.00 11.76 5.84 32
Illegal injection use 2.36 4.35 6.25 5.56 1.50 16
c2 = 95.23, df = 11, P < 0.0001**
*: Distributed in the descending order of prevalence and shown as percent occurrence; **: Statistically highly signiﬁcant; Chi-test was carried out
through the values in HBV and un-infected subjects.
Table 4
Clinical symptoms and complications associated with hepatitis infection among the scrutinized patients.
Clinical symptoms* Type of infection Total (n = 946)
HBV (n = 212) HDV (n = 23) HCV (n = 16) HBV + HCV/HDV (n = 36) Un-infected (n = 734)
Abdominal discomfort 79.25 78.26 81.25 80.56 22.48 333
Fatigue 72.64 56.52 81.25 66.67 11.72 240
Anorexia 66.04 65.22 62.50 66.67 21.66 299
Malaise 61.79 65.22 68.75 66.67 11.44 215
Fever 53.77 47.83 50.00 50.00 22.75 281
Dark urine 44.34 43.48 31.25 38.89 12.26 184
Jaundice 26.42 26.09 37.50 30.56 11.85 143
Splenomegaly 0.94 0.00 0.00 0.00 8.58 65
c2 = 103.9, df = 7, P < 0.0001**
*: Distributed in the descending order of prevalence and shown as percent occurrence; **: Statistically highly signiﬁcant; Chi-test was carried out
through the values in HBV and un-infected subjects.
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Viral hepatitis remains one of the most formidable challenges
in Pakistan. National vaccination program against hepatitis B, as
a part of global effort to reduce the burden of the disease has
already been launched in the country. However, lack of national
surveillance program and large scale community based studies
may undermine the outcome of immunization program in the
long run, particularly because there is a scarcity of the data about
prevalence of HBV/HDV infections among general population
of Pakistan across different regions. With a particular focus on
outpatient department patients with no prior history of any kind
of hepatitis altogether 946 patients were screened for HBV
infection. Out of these 22.45% were found positive for HBsAg.
Previously, different prevalence rates of HBV infection were
reported from Pakistan ranging from minimal 5% to maximal
41.26% [9,12,13].
In this study, serological scrutiny conﬁrmed that 86.79% of
the HBV infected patients were positive for anti-HBc-total.
Detection of both HBsAg and anti-HBc-total has been docu-
mented in chronic patients while HBeAg may or may not be
detected in such patients [14]. Hence, detection of anti-HBc-total,
alone may not sufﬁce an evidence for chronic HBV infection in
these patients. However, detection of anti-HBc-total in the
presence of viral DNA in such patients may reﬂect active
presence of HBV infection that is likely to proceed towards
chronic stage. In this study, viral DNA was detected in 53.77%of the anti-HBc-total positive patients which are at the higher
risk of developing chronic disease. Moreover, due to the active
state of their infection these individual pose a risk for further
dissemination of HBV infection. While majority of the HBsAg
positive patients were also positive for anti-HBc-total, 25%
showed presence of anti-HBc-IgM, which is considered as an
important serological marker to diagnose recent HBV infections,
in so-called “window period”.
Among HBsAg positive samples, screening for co-infection
of HDV was one the most important aspect of this study.
Seroprevalence of HDV varies greatly across different countries,
for example, in Turkey, Saudi Arabia and Bangladesh preva-
lence rates were observed 5.2%, 3.3% and 24.4%, respectively
[15,16]. Previously, only few studies have been conducted to
assess the seroprevalence of HDV in Pakistan and
demonstrated some inconsistencies [9,17]. Observed differences
in seroprevalence of HDV in these studies were attributed to
several factors, including different geographical locations,
population differences and detection methods used (RNA or
anti-HDV). Based on anti-HDV detection prevalence rate for
HDV infection in this study appeared to be 10.84%. Notably, it
is the ﬁrst report from Pakistan which highlights the prevalence
of HBV/HDV co-infection in a population with no prior history
of viral hepatitis.
Prevalence of co-infection with HCV varies among infected
HBV patients ranging from 10% to 20% [18]. HCV infections are
reported among different groups of patients having organ
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thalassemia [19–24]. Co-infection with HDV/HCV leads to
deleterious clinical outcomes including cirrhosis and hepato-
cellular carcinoma [25]. In our study 7.4% of HBsAg positive
patients were co-infected with HCV.
Generally, a wide range of clinical manifestations are asso-
ciated with HBV infections including asymptomatic sero-
conversion, non-speciﬁc symptoms (anorexia, nausea, etc.) and
extra hepatic symptoms. We observed signiﬁcantly higher as-
sociation of HBV infection with various symptoms, including
abdominal discomfort, fatigue, anorexia, malaise, fever, dark
urine, jaundice and splenomegaly. Abdominal discomfort was
one of the most prominent symptoms associated with HBV
infection in this study. Similarly, signiﬁcant association of
different risk factors and HBV infection was also observed.
Overall use of injection was the major risk factor that followed
intravenus infusion.
Conclusively, from KPK region, it is the ﬁrst report which
highlights HBV/HDV infection in outpatient department patients
which indicates higher prevalence of HBV/HDV infection in pa-
tients with no prior history of any kind of hepatitis and majority of
these patients belong to younger age group. In addition, serolog-
ical and viral DNA based evidence suggest active prevalence of
HBV infection among majority of the patients which indicates
higher risk of further HBV transmission by these patients.Conﬂict of interest statement
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